Compare CSTL & ENVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTL | ENVX |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.8M | 741.7M |
| IPO Year | 2019 | 2020 |
| Metric | CSTL | ENVX |
|---|---|---|
| Price | $34.49 | $3.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $45.50 | $13.61 |
| AVG Volume (30 Days) | 275.5K | ★ 5.3M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 40.94 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $344,229,000.00 | $31,821,000.00 |
| Revenue This Year | $2.42 | $30.37 |
| Revenue Next Year | $12.69 | $238.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 3.66 | ★ 37.91 |
| 52 Week Low | $17.72 | $2.85 |
| 52 Week High | $44.28 | $14.21 |
| Indicator | CSTL | ENVX |
|---|---|---|
| Relative Strength Index (RSI) | 58.21 | 34.17 |
| Support Level | $22.88 | N/A |
| Resistance Level | $42.03 | $3.55 |
| Average True Range (ATR) | 1.44 | 0.15 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 57.86 | 19.29 |
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, the United States, Norway, Taiwan, and other regions.